Sanjay Keswani, M.D.

Sanjay Keswani, M.D.

Chief Medical Officer Jude Onyia, Ph.D.atNeurocrine Biosciences· In proxies 2023–2025

Pay in FY2023Neurocrine Biosciences stock +10.3% the same year

Sanjay Keswani, M.D. was paid $7.2M in FY2023 (Dec). Neurocrine Biosciences stock rose 10.3% that year.

Pay$100 in the stock at the end of FY22 → $110
Pay is from the Summary Compensation Table of each Neurocrine Biosciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Neurocrine BiosciencesPublic company · 3 yr
    • Chief Medical Officer Jude Onyia, Ph.D.2023 – Present · 3 yrStock in role +22%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?